User profiles for Rand A. Alattar
 | Rand A. AlattarHMC Verified email at hamad.qa Cited by 388 |
Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report
…, A Baiou, J Daghfal, N Elkum, RA Alattar… - Journal of Medical …, 2021 - Wiley Online Library
Background The role of convalescent plasma therapy for patients with coronavirus disease
2019 (COVID‐19) is unclear. Methods We retrospectively compared outcomes in a cohort of …
2019 (COVID‐19) is unclear. Methods We retrospectively compared outcomes in a cohort of …
[HTML][HTML] The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study
…, MA Almaslamani, J Daghfal, RA Alattar… - BMC infectious …, 2020 - Springer
Background There are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at
a national level, and none after 60 days of follow up. The aim of this study was to describe …
a national level, and none after 60 days of follow up. The aim of this study was to describe …
Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs
M A. Elrayess, H T. Zedan, R A. Alattar, H Abusriwil… - Blood …, 2022 - Taylor & Francis
Purpose This study examines the effect of antihypertensive drugs on ACE2 and Angiotensin
II levels in hypertensive COVID-19 patients. Introduction Hypertension is a common …
II levels in hypertensive COVID-19 patients. Introduction Hypertension is a common …
Tocilizumab for the treatment of severe coronavirus disease 2019
Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory manifestations
associated with severe coronavirus disease 2019 (COVID‐19) and thus improve clinical …
associated with severe coronavirus disease 2019 (COVID‐19) and thus improve clinical …
[HTML][HTML] Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
RA Alattar, S Abdalla, T Abdallah, R Kazman… - Journal of Infection and …, 2022 - Elsevier
We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19
pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of …
pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of …
[HTML][HTML] Coronavirus disease 2019 in solid organ transplant recipients in the setting of proactive screening and contact tracing of Qatar
RA Alattar, SH Shaar, M Othman, SH Abu Jarir… - Qatar Medical …, 2021 - qscience.com
Background: Clinical data on Coronavirus Disease 2019 (COVID-19) in solid organ transplant
(SOT) recipients are limited. We herein report the initial clinical experience with COVID-19 …
(SOT) recipients are limited. We herein report the initial clinical experience with COVID-19 …
Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study
RA Alattar, S Abdalla, TAK Abdallah, R Kazman… - medRxiv, 2021 - medrxiv.org
Background We investigated clinical outcomes of favipiravir in patients with COVID-19
pneumonia. Methods Patients who between 23 May 2020 and 18 July 2020 received ≥24 hours …
pneumonia. Methods Patients who between 23 May 2020 and 18 July 2020 received ≥24 hours …
Coronavirus disease 2019 in solid organ transplant recipients in a setting of proactive screening and contact tracing
RA Alattar, SH Shaar, M Othman… - Journal of Emergency …, 2021 - qscience.com
Background: As of 26 June 2020, the global number of infections caused by Severe Acute
Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), had reached 11 million, with more than …
Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), had reached 11 million, with more than …
Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study (preprint)
RA ALATTAR, S Abdalla, TAK Abdallah, R Kazman… - 2021 - pesquisa.bvsalud.org
Background We investigated clinical outcomes of favipiravir in patients with COVID-19
pneumonia. Methods Patients who between 23 May 2020 and 18 July 2020 received 24 hours or …
pneumonia. Methods Patients who between 23 May 2020 and 18 July 2020 received 24 hours or …
The First Consecutive 5000 Patients with Coronavirus Disease 2019 from Qatar; a Nation-wide Cohort Study (preprint)
BackgroundThere are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at a
national level, and none after 60 days of follow up. The aim of this study was to describe …
national level, and none after 60 days of follow up. The aim of this study was to describe …